Eiger BioPharmaceuticals, Inc.
NasdaqGM:EIGR
$ 2.25
+ $0.13 (6.13%)
$ 2.25
+ $0.13 (6.13%)
End-of-day quote: 05/15/2024

Eiger BioPharmaceuticals financials at a glance

The revenue of Eiger BioPharmaceuticals is reported as 0.01577 billion Dollars in the fiscal year 2023. The earnings were -50.78 Dollars per share in 2023, which was 27.04 higher than 2022. And about -4.0E-5 billion Dollars are reported as free cash flow in the financials of Eiger BioPharmaceuticals 2023. No dividends were paid to the shareholders of the Eiger BioPharmaceuticals stock NasdaqGM:EIGR in the financial year 2023.

$15.77M
Revenue
$-50.78
Earnings Per Share
99.85%
Gross Margin %
$0.00M
Free Cash Flow
Revenue
15.77
Earnings Per Share
-50.78
Gross Margin %
99.85
Free Cash Flow
0.00

Financials

Year Year TTM 2023 2022 2021 2020 2019 2018 2017 2016 2015
Rev. Revenue N/A $15.77M $13.48M $12.14M $0.00M $0.00M $0.00M $0.00M $0.00M $0.00M
GM % Gross Margin % 98.17% 99.85% 86.38% 11.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
OM Operating Margin 0.00% 0.00% 0.00% -6.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Earnings Per Share $-1.96 $-50.78 $-69.60 $-30.00 $-69.30 $-92.40 $-,114.60 $-,145.80 $-,235.20 $-,150.00
Div. Dividends N/A $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
PR % Payout Ratio % 0 -0.00% -0.00% -0.00% -0.00% -0.00% 0 0 0 0
Sha. Shares N/AM 1.48M 1.47M 1.15M 1.13M 0.82M 0.64M 0.35M 0.28M 0M
OCF Operating Cash Flow N/A $0.00M $0.00M $-71.29M $-63.19M $-63.61M $-42.67M $-38.37M $0.00M $0.00M
FCF Free Cash Flow N/A $0.00M $0.00M $-,225,071.29M $-63.45M $-64.09M $-42.81M $-38.41M $0.00M $0.00M
FCFS Free Cash Flow Per Share $-1.88 $-50.66 $-60.07 $-2.10 $-2.25 $-2.81 $-3.14 $-4.38 $-6.33 $-42.85